$GRCE News
Last published 6d ago
- 6d agoGRCEGrace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026GlobeNewswirePRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1mo agoGRCEGRACE THERAPEUTICS, INC Annual Meeting of Stockholders - GRACE THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Grace Therapeutics, Inc.'s 2026 Annual Meeting of Stockholders. During the meeting, we will have a question and answer session. You can submit questions at any time by navigating to the Ask a Questi
- 1mo agoGRCEGRACE THERAPEUTICS, INC ANNUAL MEETING OF STOCKHOLDERS - GRACE THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Grace Therapeutics, Inc.'s 2026 Annual Meeting of Stockholders. During the meeting, we will have a question and answer session. You can submit questions at any time by navigating to the Ask a Questi
- 1mo agoGRCEANNUAL MEETING OF STOCKHOLDERS - GRACE THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Grace Therapeutics, Inc.'s 2026 Annual Meeting of Stockholders. During the meeting, we will have a question and answer session. You can submit questions at any time by navigating to the Ask a Questi
- 2mo agoGRCEGrace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment ConferenceGlobeNewswirePRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 3mo agoGRCEGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business UpdateGlobeNewswirePRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 3mo agoGRCEGrace Therapeutics Announces $10 Million Private PlacementGlobeNewswirePRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) ("Grace Therapeutics" or "the Company"), a late-stage, biopharma company advancing GTx-104, a clinical-stage,
- 3mo agoGRCEGrace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationGlobeNewswireFDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission
- 4mo agoGRCEGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateGlobeNewswireType A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial
- 6mo agoGRCEGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104GlobeNewswireFDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit
- 7mo agoGRCEGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026GlobeNewswirePRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 8mo agoGRCEGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswirePRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 9mo agoGRCEGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateGlobeNewswireFDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data
- 11mo agoGRCEGrace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferenceGlobeNewswirePRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 12mo agoGRCEGrace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business UpdateGlobeNewswireAnnounced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104
- 1y agoGRCEGrace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual MeetingGlobeNewswirePRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEGrace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA ReviewGlobeNewswirePRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEGrace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual MeetingGlobeNewswirePRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEGrace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104GlobeNewswireGrant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025
- 1y agoGRCEGrace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswirePRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEGrace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104GlobeNewswireFDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported
- 1y agoGRCEGrace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business UpdateGlobeNewswireSubmission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported
- 1y agoGRCEGrace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104GlobeNewswireSubmission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104
- 1y agoGRCEGrace Therapeutics to Participate in the 2025 BIO International ConferenceGlobeNewswirePRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEGrace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104GlobeNewswirePRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable
- 1y agoGRCEMTNBONVOMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireBEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of
- 1y agoGRCEGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceGlobeNewswirePRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a
- 1y agoGRCEGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateGlobeNewswireAnnounced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025
- 1y agoGRCEGrace Therapeutics Announces Private Placement Financing of up to $30 MillionGlobeNewswireFinancing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an
- 1y agoGRCEGrace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHGlobeNewswireTrial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb.
- 1y agoACSTGRCEGrace Therapeutics to Participate in Upcoming Investor Events January 2025GlobeNewswirePRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing
- 1y agoACSTGRCEGrace Therapeutics to Exhibit at the American Society of Health-System Pharmacists ConferenceGlobeNewswirePRINCETON, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) formerly Acasti Pharma Inc. (NASDAQ:ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing
- 1y agoGRCEGrace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business UpdateGlobeNewswireSTRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025 Completed Corporate Re-Branding, Connecting Company to Rich Scientific Legacy of Grace Therapeutics Announced
- 2y agoGRCEGrace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024GlobeNewswirePRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, its novel injectable formulation of